Is Philip Morris Stock Overvalued?
If there is one industry that can be termed truly…
Buy
58
CHGCF Quote, Financials, Valuation and Earnings
Last price:
$42.42
Seasonality move
:
7.55%
Day range:
$39.83 - $44.63
52-week range:
$29.75 - $52.22
Dividend yield:
1.22%
P/E ratio:
27.12x
P/S ratio:
9.23x
P/B ratio:
5.53x
Volume:
21.2K
Avg. volume:
10.3K
1-year change:
14.64%
Market cap:
$69.8B
Revenue:
$7.9B
EPS (TTM):
$1.56
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Chugai Pharmaceutical has -- downside to fair value with a price target of -- per share.
CHGCF vs. S&P 500
-
Over the past 5 trading days, Chugai Pharmaceutical has underperformed the S&P 500 by -6.49% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Chugai Pharmaceutical does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Chugai Pharmaceutical has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Chugai Pharmaceutical reported revenues of $2.1B.
Earnings Growth
-
Chugai Pharmaceutical has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Chugai Pharmaceutical reported earnings per share of $0.45.
Enterprise value:
63.9B
EV / Invested capital:
--
Price / LTM sales:
9.23x
EV / EBIT:
17.75x
EV / Revenue:
8.40x
PEG ratio (5yr expected):
4.48x
EV / Free cash flow:
26.29x
Price / Operating cash flow:
28.87x
Enterprise value / EBITDA:
17.75x
Gross Profit (TTM):
$5.4B
Return On Assets:
19.59%
Net Income Margin (TTM):
33.85%
Return On Equity:
22.92%
Return On Invested Capital:
22.92%
Operating Margin:
50.81%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $9.4B | $9.2B | $7.6B | $1.8B | $2.1B | |
| Gross Profit | $6.3B | $5.3B | $5.4B | $1.2B | $1.6B | |
| Operating Income | $4.3B | $3.4B | $3.6B | $738.6M | $1.1B | |
| EBITDA | $4.3B | $3.4B | $3.6B | $744.1M | $1.1B | |
| Diluted EPS | $1.86 | $1.47 | $1.56 | $0.33 | $0.45 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $7B | $8.2B | $8.2B | $8.4B | $10.4B | |
| Total Assets | $10.8B | $12.1B | $11.8B | $12.2B | $14.5B | |
| Current Liabilities | $1.7B | $2.2B | $2.6B | $1.8B | $1.8B | |
| Total Liabilities | $2B | $2.3B | $2.7B | $1.9B | $1.9B | |
| Total Equity | $8.8B | $9.7B | $9.1B | $10.3B | $12.6B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $2.8B | $1.9B | $2.9B | $123.9M | $886.9M | |
| Cash From Investing | -$1.1B | -$519.1M | -$1.4B | $30.2M | -$307.9M | |
| Cash From Financing | -$1.1B | -$1B | -$980M | -$441.1M | -$490M | |
| Free Cash Flow | $2.3B | $1.4B | $2.4B | $76.1M | $750M | |
CHGCF
Sector
Market Cap
$69.8B
$45.7M
Price % of 52-Week High
81.22%
47.48%
Dividend Yield
1.22%
0%
Shareholder Yield
1.12%
-0.75%
1-Year Price Total Return
14.64%
-32.34%
Beta (5-Year)
0.105
0.746
Dividend yield:
1.22%
Annualized payout:
$0.56
Payout ratio:
35.92%
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$43.13
200-day SMA
Buy
Level
$40.17
Bollinger Bands (100)
Sell
Level
42.19 - 49.09
Chaikin Money Flow
Buy
Level
104.2K
20-day SMA
Sell
Level
$43.40
Relative Strength Index (RSI14)
Sell
Level
48.25
ADX Line
Buy
Level
32.49
Williams %R
Neutral
Level
-60.6338
50-day SMA
Sell
Level
$43.07
MACD (12, 26)
Sell
Level
-0.05
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
353.9K
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
Buy
CA Score
(Annual)
Level (2.1575)
--
Beneish M-Score
(Annual)
Level (--)
--
Momentum Score
Level (--)
Buy
Ohlson Score
Level (-6.1601)
Buy
Piotroski F Score
(Annual)
Level (6)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding Ltd, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan’s oncology market for the past decade, largely due to drugs licensed from its parent’s portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several notable therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and COVID-19.
Stock Forecast FAQ
In the current month, CHGCF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CHGCF average analyst price target in the past 3 months is --.
-
Where Will Chugai Pharmaceutical Stock Be In 1 Year?
According to analysts, the consensus estimate is that Chugai Pharmaceutical share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Chugai Pharmaceutical?
Analysts are divided on their view about Chugai Pharmaceutical share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Chugai Pharmaceutical is a Sell and believe this share price will rise from its current level to --.
-
What Is Chugai Pharmaceutical's Price Target?
The price target for Chugai Pharmaceutical over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CHGCF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Chugai Pharmaceutical is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of CHGCF?
You can purchase shares of Chugai Pharmaceutical via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Chugai Pharmaceutical shares.
-
What Is The Chugai Pharmaceutical Share Price Today?
Chugai Pharmaceutical was last trading at $42.42 per share. This represents the most recent stock quote for Chugai Pharmaceutical. Yesterday, Chugai Pharmaceutical closed at $42.42 per share.
-
How To Buy Chugai Pharmaceutical Stock Online?
In order to purchase Chugai Pharmaceutical stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Quantum Stocks Should I Buy?
The last several years have seen a series of tech…
Will Sirius XM Be a 10-Bagger Stock?
Last year, Warren Buffett surprised practically everyone when he acquired…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
49
RKLB alert for Jan 22
Rocket Lab USA [RKLB] is up 30.42% over the past day.
Sell
32
FTAI alert for Jan 22
FTAI Aviation [FTAI] is down 25.44% over the past day.
Sell
2
EDU alert for Jan 22
New Oriental Education & Technology Group [EDU] is down 23.18% over the past day.
